Found 1 structure.
Displayed structure 1
Expand all compounds
Collapse all compounds
Show all as text (SweetDB notation)
Show all graphically (SNFG notation)
1. Compound ID: 15924
a-Neup5Ac-(2-3)-b-D-Galp-(1-4)-+
|
b-D-GlcpNAc-(1-3)-b-D-Galp-(1-4)-b-D-Glcp-(1-6)-b-D-GlcpNAc-(1--/3-aminopropyl/ |
Show graphically |
Structure type: oligomer
Aglycon: 3-aminopropyl
Trivial name: glycan epitope (glycotope)
Compound class: CPS
Contained glycoepitopes: IEDB_1083493,IEDB_1083495,IEDB_130646,IEDB_135813,IEDB_136044,IEDB_136794,IEDB_137340,IEDB_137472,IEDB_1391966,IEDB_140108,IEDB_140122,IEDB_141794,IEDB_141807,IEDB_142351,IEDB_142487,IEDB_142488,IEDB_146100,IEDB_146664,IEDB_149138,IEDB_149143,IEDB_149174,IEDB_150933,IEDB_151531,IEDB_190606,IEDB_423120,IEDB_983931,SB_115,SB_116,SB_131,SB_145,SB_165,SB_166,SB_170,SB_171,SB_172,SB_173,SB_187,SB_192,SB_195,SB_30,SB_39,SB_6,SB_68,SB_7,SB_84,SB_88
The structure is contained in the following publication(s):
- Article ID: 6170
Zaslona ME, Downey AM, Seeberger PH, Moscovitz O "Semi- and fully synthetic carbohydrate vaccines against pathogenic bacteria: recent developments" -
Biochemical Society Transactions 49(5) (2021) 2411-2429
The importance of vaccine-induced protection was repeatedly demonstrated over the last three decades and emphasized during the recent COVID-19 pandemic as the safest and most effective way of preventing infectious diseases. Vaccines have controlled, and in some cases, eradicated global viral and bacterial infections with high efficiency and at a relatively low cost. Carbohydrates form the capsular sugar coat that surrounds the outer surface of human pathogenic bacteria. Specific surface-exposed bacterial carbohydrates serve as potent vaccine targets that broadened our toolbox against bacterial infections. Since first approved for commercial use, antibacterial carbohydrate-based vaccines mostly rely on inherently complex and heterogenous naturally derived polysaccharides, challenging to obtain in a pure, safe, and cost-effective manner. The introduction of synthetic fragments identical with bacterial capsular polysaccharides provided well-defined and homogenous structures that resolved many challenges of purified polysaccharides. The success of semisynthetic glycoconjugate vaccines against bacterial infections, now in different phases of clinical trials, opened up new possibilities and encouraged further development towards fully synthetic antibacterial vaccine solutions. In this mini-review, we describe the recent achievements in semi- and fully synthetic carbohydrate vaccines against a range of human pathogenic bacteria, focusing on preclinical and clinical studies.
carbohydrates, capsular polysaccharides, bacteria, vaccines, synthetic carbohydrate, antibacterial vaccines
NCBI PubMed ID: 34495299Publication DOI: 10.1042/BST20210766Journal NLM ID: 7506897Correspondence: Oren Moscovitz
Institutions: Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany, Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany
Expand this compound
Collapse this compound
Total list of structure IDs on all result pages of the current query:
Total list of corresponding CSDB IDs (record IDs):
Execution: 1 sec